PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Context: Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction is unknown. Objective: We tested the hypothesis that the PCSK9 R46L loss-of-function mutation is associated with lower levels of lipoprotein(a) and with reduced risk of aortic valve stenosis and myocardial infarction. Design: We used two prospective cohort studies of the general population and one patient-based cohort. Setting: Cohort studies selected at random individuals of Danish descent. Participants: We studied 103 083 individuals from the Copenhagen General Population Study, the Copenhagen City Heart Study, and the Copenhagen Ischemic Heart Disease Study. Main outcome measures: Lipoprotein(a), LDL cholesterol, and PCSK9 R46L genotype and diagnoses of aortic valve stenosis and myocardial infarction from national registries; lipoprotein(a) was measured from 49,617 individuals. Results: Median (interquartile range) lipoprotein(a) levels were 10 (5–30) mg/dl for PCSK9 R46L noncarriers, 9 (4–32) mg/dl for heterozygotes, and 8 (4–42) mg/dl for homozygotes (trend P = .02). The corresponding values for LDL cholesterol levels were 124 (101–147) mg/dl, 104 (85–132) mg/dl, and 97 (85–128) mg/dl, respectively (trend P = 2 × 10−52). PCSK9 R46L carriers vs noncarriers had an age- and sex-adjusted odds ratio of 0.64 (95% confidence interval, 0.44–0.95) for aortic valve stenosis, 0.77 (0.65–0.92) for myocardial infarction, and 0.76 (0.64–0.89) for aortic valve stenosis or myocardial infarction. Conclusions: PCSK9 R46L carriers have lower levels of lipoprotein(a) and LDL cholesterol as well as reduced risk of aortic valve stenosis and myocardial infarction. This indirectly suggests that PCSK9 inhibitors may have a role in patients with aortic valve stenosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 5×
“Specifically, the PCSK9 R46L loss-of-function mutation has been associated with lower levels of LDL cholesterol and with reduced risk of ischemic heart disease and MI (11, 13, 14).”
BackgroundResultInfluentialEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 2×
“However, PCSK9 inhibitor treatment has also been shown to lower lipoprotein(a) (15, 16).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 2×
“The Copenhagen City Heart Study is a prospective study of the general population initiated in 1976–1978 with follow-up examinations in 1981–1983, 1991–1994, and 2001–2003 (18).”
BackgroundSelf-citationClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 2×
“Recently, however, several other risk factors similar to those for coronary artery disease have emerged and include smoking, high blood pressure, high cholesterol, diabetes, and male sex (25).”
BackgroundLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807 · cited 1×
“A limitation of our study is that we included only white individuals of Danish descent and this may limit the applicability to other ethnicities, especially because lipoprotein(a) levels differ among different ethnic groups (6, 7, 27).”
BackgroundSelf-citation(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357 · cited 2×
“One of the most important genetic determinants for lipoprotein(a) levels is the Kringle IV type 2 (KIV-2) size polymorphism, which is inversely associated with lipoprotein(a) levels; the KIV-2 number of repeats was determined by real-time PCR analysis (5).”
BackgroundMethodSelf-citationA Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008 · cited 1×
“very recently it has been shown that elevated levels of lipoprotein(a) is a likely causal risk factor for aortic valve stenosis (8, 10).”
BackgroundSelf-citationLipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815 · cited 1×
“Elevated lipoprotein(a) has previously been causally associated with increased risk of aortic valve stenosis (8–10), whereas large statin trials with effective LDL cholesterol lowering have failed to have an impact on aortic valve stenosis (24).”
BackgroundElevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595 · cited 2×
“Before all analyses, lipoprotein(a) measurements were uniformly calibrated to Denka Seiken levels to avoid bias resulting from the use of different assays, as done previously (10).”
BackgroundMethodSelf-citationKamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 558 · cited 3×
“For the in-house assay, isoform-insensitivity of the polyclonal antibody was established by Western blotting targeting approximately 10 different isoforms of lipoprotein(a) with adequate detection of all isoforms and with no tendency for the larger isoforms to have increased signal intensity (2).”
MethodResultSelf-citationLipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521 · cited 3×
“Lipoprotein(a) consists of an LDL particle with apolipoprotein B100 bound to apolipoprotein(a), a large glycoprotein that resembles plasminogen (7).”
BackgroundPCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Lagace, T. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000114 · Cited by 372 · cited 1×
“Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a serine protease that promotes the degradation of the LDL receptor (11, 12).”
BackgroundReduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 361 · cited 2×
“That the PCSK9 R46L loss-of-function mutation, and likewise treatment with PCSK9 inhibitors (23), lowers LDL cholesterol is well-established (11, 13, 14).”
BackgroundArsenault, B. J., Boekholdt, S. M., Dubé, M.-P., Rhéaume, É., Wareham, N. J., Khaw, K.-T., Sandhu, M. S., & Tardif, J.-C. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000400 · Cited by 315
PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
Benn, M., Nordestgaard, B. G., Grande, P., Schnohr, P., & Tybjærg-Hansen, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.044 · Cited by 314 · cited 5×
“Specifically, the PCSK9 R46L loss-of-function mutation has been associated with lower levels of LDL cholesterol and with reduced risk of ischemic heart disease and MI (11, 13, 14).”
BackgroundMethodResultSelf-citationMarcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288 · cited 1×
“The Denka Seiken assay has previously been documented isoform insensitive by comparison with a reference ELISA (19).”
MethodSmith, J. G., Luk, K., Schulz, C.-A., Engert, J. C., Do, R., Hindy, G., Rukh, G., Dufresne, L., Almgren, P., Owens, D. S., et al. (2014) · JAMA · doi:10.1001/jama.2014.13959 · Cited by 238 · cited 2×
“Another possible explanation could be the more profoundly reduced levels of LDL cholesterol (11, 13, 29) because high LDL cholesterol levels also seem to be a causal risk factor for aortic valve stenosis (17).”
BackgroundRader, D. J., Cain, W., Ikewaki, K., Talley, G., Zech, L. A., Usher, D., & Brewer, H. B. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117292 · Cited by 236 · cited 1×
“(26), and the pathway for clearance of lipoprotein(a) is at present not fully elucidated (7, 27).”
BackgroundStein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu085 · Cited by 130 · cited 2×
“However, PCSK9 inhibitor treatment has also been shown to lower lipoprotein(a) (15, 16).”
BackgroundVascular Calcifications in Homozygote Familial Hypercholesterolemia
Awan, Z., Alrasadi, K., Francis, G. A., Hegele, R. A., McPherson, R., Frohlich, J., Valenti, D., de Varennes, B., Marcil, M., Gagne, C., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160408 · Cited by 98 · cited 1×
“The LDL receptor has a potential role in aortic valve stenosis and patients with familial hypercholesterolemia also develop premature aortic calcification; however, it seems that aortic valve calcification does not correlate with total and LDL cholesterol levels and that calcification develops despite sufficient lipid…”
BackgroundScartezini, M., Hubbart, C., Whittall, R. A., Cooper, J. A., Neil, A. H. W., & Humphries, S. E. (2007) · Clinical Science · doi:10.1042/cs20070150 · Cited by 96 · cited 2×
“That the PCSK9 R46L loss-of-function mutation, and likewise treatment with PCSK9 inhibitors (23), lowers LDL cholesterol is well-established (11, 13, 14).”
BackgroundLipoprotein(a)-cholesterol: A significant component of serum cholesterol
Kinpara, K., Okada, H., Yoneyama, A., Okubo, M., & Murase, T. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.05.036 · Cited by 67 · cited 1×
“In all analyses, for each individual total cholesterol, LDL cholesterol and apolipoprotein B were corrected for the lipoprotein(a) contribution by subtracting either 30% of total lipoprotein(a) mass(corresponding to the cholesterol content in lipoprotein(a)) from total cholesterol and LDL cholesterol, or 16% of total…”
BackgroundHallman, D. M., Srinivasan, S. R., Chen, W., Boerwinkle, E., & Berenson, G. S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.057 · Cited by 54 · cited 2×
“Another possible explanation could be the more profoundly reduced levels of LDL cholesterol (11, 13, 29) because high LDL cholesterol levels also seem to be a causal risk factor for aortic valve stenosis (17).”
BackgroundResultRonald, J., Rajagopalan, R., Cerrato, F., Nord, A. S., Hatsukami, T., Kohler, T., Marcovina, S., Heagerty, P., & Jarvik, G. P. (2011) · Stroke · doi:10.1161/strokeaha.110.591230 · Cited by 47 · cited 1×
“Further, there are several other critical lipid associated genes where a clear association of the genetic variation with lipoprotein(a) levels has been established (28), and such genetic variation might influence the risk of aortic valve stenosis, although this needs to be tested.”
BackgroundFantus, D., Awan, Z. A., Seidah, N. G., & Genest, J. J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.026 · Cited by 36 · cited 1×
“The LDL receptor has a potential role in aortic valve stenosis and patients with familial hypercholesterolemia also develop premature aortic calcification; however, it seems that aortic valve calcification does not correlate with total and LDL cholesterol levels and that calcification develops despite sufficient lipid…”
Background
Research works printed but not linked: 1
- Utermann, 2001, Lipoprotein(a), 2753
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citationTsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 501
Gaba, P., O’Donoghue, M. L., Park, J.-G., Wiviott, S. D., Atar, D., Kuder, J. F., Im, K., Murphy, S. A., De Ferrari, G. M., Gaciong, Z. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063399 · Cited by 184
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Metadata
- Authors
- Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R.
- Affiliations
- University of Copenhagen (DK)
- Frederiksberg Hospital (DK)
- The Copenhagen General Population Study (A.L., B.G.N., M.B., A.T.-H., P.R.K.), Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
- Corresponding author
- Kamstrup, Pia R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-24
- Volume
- 101
- Issue
- 9
- Pages
- 3281-3287
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2404696858
- Cited by
- 136
- References
- 33
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 20 · 2023: 17 · 2022: 13 · 2021: 14 · 2020: 13 · 2019: 9 · 2018: 15 · 2017: 8 · 2016: 1
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Sanofi
- Fresenius Medical Care North America
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, loss-of-function mutations, lipoprotein(a), LDL cholesterol, aortic stenosis, myocardial infarction, PCSK9 inhibitors, genetic association, cardiovascular risk, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease prevention, Danish population, Copenhagen General Population Study, Copenhagen City Heart Study
- MeSH terms
- Proprotein Convertase 9, Adult, Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Follow-Up Studies, Genotype, Heterozygote, Humans, Cholesterol, LDL, Male, Middle Aged, Mutation, Myocardial Infarction, Prognosis, Prospective Studies, Risk Factors, Biomarkers, Lipoprotein(a), Genetic Predisposition to Disease, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.